16 drugmakers announce TrumpRx pricing agreements and direct-to-patient discounts

U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-year exemptions from tariffs on drug imports. Drugmakers committed to “most-favoured-nation” pricing, to sell drugs directly to consumers through a new government platform called TrumpRx.gov and pledged billions of dollars in U.S. investments. Trump sent letters to the leaders of 17 large pharma companies in July demanding that they match U.S. prices of their new drugs with the lowest prices offered in other developed nations, with 16 of them publicly announcing agreements with the government.

Pfizer in September agreed to lower prescription drug prices for American patients, including discounts of up to 85% through TrumpRx.gov. The company said a majority of its primary care treatments and some select brands, including Xeljanz, Eucrisa and Duavee, will be offered at average savings of 50% which can be as high as 85%.

Johnson & Johnson in January agreed to lower drug prices for American patients, including through the TrumpRx.gov platform, but specific terms of the agreement were not disclosed, including details on revised drug prices or which medicines are covered. AstraZeneca in October agreed to lower prescription drug prices for American patients, including discounts of up to 80% through TrumpRx.gov.

Novo Nordisk in November agreed to reduce prices for its semaglutide medicines, including Wegovy and Ozempic, for American patients through Medicare, Medicaid, and a direct-to-patient cash channel. Prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx. Novo Nordisk will also provide insulin products including NovoLog and Tresiba at $35 per month through TrumpRx.

Eli Lilly in November agreed to offer Medicare beneficiaries its obesity medicines Zepbound and orforglipron, branded as Foundayo, at no more than $50 per month, with additional discounts for self-pay patients through LillyDirect. The Zepbound multidose pen will be available at $299 per month at the lowest dose, with additional doses priced up to $449, while Foundayo will be available starting at $149 per month at its lowest dose through LillyDirect. Lilly will also offer Emgality at $299 per pen and Trulicity at $389 per month through TrumpRx.

AbbVie in January agreed to lower drug prices through Medicaid and expand direct-to-patient offerings via TrumpRx for medicines including Humira and Synthroid. Bristol Myers Squibb said in December it will provide Eliquis to Medicaid for free as part of its deal with the Trump administration and agreed to donate more than seven tons of active pharmaceutical ingredient for Eliquis.

Gilead Sciences said in December it will provide select medicines to treat HIV, hepatitis C, hepatitis B and COVID-19 at a discounted price for Medicaid beneficiaries. It agreed to price future medicines at parity with other key developed nations and make its hepatitis C treatment, Epclusa, available at a discounted cash price through TrumpRx and its own direct-to-patient program.

Merck KGaA unit EMD Serono said in October it would sell fertility treatments including Gonal-f, Ovidrel and Cetrotide directly to consumers with a combined discount of 84% off list price if three of them were used in IVF, and would offer all new drugs launched in the U.S. at the prices it charges in other developed countries. Merck in December said it will sell its diabetes drugs Januvia, Janumet and Janumet XR directly to U.S. consumers at about 70% off list prices, and if approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels including TrumpRx.

Roche unit Genentech said in December it would lower prices for many of its medicines under Medicaid comparable to those available in other wealthy countries and make its influenza medicines available through TrumpRx.gov and its own direct-to-patient program. Novartis said in December it would launch new drugs in the U.S. at prices comparable to other developed countries and make Mayzent, Rydapt and Tabrecta available through its direct-to-patient platform and TrumpRx.gov.